The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment

被引：69

作者：

Fornier, Monica ^{[1
]}

Fumoleau, Pierre ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY USA

[2] Ctr Georges Francois Leclerc, Dijon, France

来源：

BREAST JOURNAL | 2012年 / 18卷 / 01期

关键词：

ixabepilone; novel agents; poly(ADP-ribose) polymerase; platinum agents; triple-negative breast cancer; ERIBULIN MESYLATE E7389; MOLECULAR SUBTYPES; DNA-REPAIR; RECEPTOR; BASAL; SURVIVAL; OUTCOMES; INHIBITOR; WOMEN; CHEMOSENSITIVITY;

D O I：

10.1111/j.1524-4741.2011.01175.x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer that lacks expression of estrogen/progesterone receptors and overexpression of the human epidermal growth factor receptor2 (HER2), i.e. triple-negative breast cancer (TNBC), is not amenable to current targeted therapies and carries a poor prognosis. This review discusses the natural history of TNBC and published literature in the relevant treatment landscape, with a focus on newer therapies. Compared with other subtypes of breast cancer, TN tumors have higher response rates to neoadjuvant chemotherapy; however, this advantage is not clearly translated into the metastatic setting and has not improved these patients overall survival. Numerous cytotoxic and targeted strategies have demonstrated efficacy or are under investigation. Strategies showing promise in this difficult-to-treat group of patients include cytotoxic therapy with platinum-containing agents, ixabepilone, and novel targeted approaches such as poly(ADP-ribose) polymerase inhibitors.

引用

页码：41 / 51

页数：11

共 85 条

[1] Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer [J].

Baselga, Jose ;

Zambetti, Milvia ;

Llombart-Cussac, Antoni ;

Manikhas, Georgy ;

Kubista, Ernst ;

Steger, Guenther G. ;

Makhson, Anatoly ;

Tjulandin, Sergei ;

Ludwig, Heinz ;

Verrill, Mark ;

Ciruelos, Eva ;

Egyhazi, Suzanne ;

Xu, Li-An ;

Zerba, Kim E. ;

Lee, Hyerim ;

Clark, Edwin ;

Galbraith, Susan .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) :526-534

[2] Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].

Bauer, Katrina R. ;

Brown, Monica ;

Cress, Rosemary D. ;

Parise, Carol A. ;

Caggiano, Vincent .

CANCER, 2007, 109 (09) :1721-1728

[3]

Bergh J, 2010, J CLIN ONCOL, V28

[4] Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer [J].

Berry, DA ;

Cirrincione, C ;

Henderson, IC ;

Citron, ML ;

Budman, DR ;

Goldstein, LJ ;

Martino, S ;

Perez, EA ;

Muss, HB ;

Norton, L ;

Hudis, C ;

Winer, EP .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14) :1658-1667

[5] How basal are triple-negative breast cancers? [J].

Bertucci, Francois ;

Finetti, Pascal ;

Cervera, Nathalie ;

Esterni, Benjamin ;

Hermitte, Fabienne ;

Viens, Patrice ;

Birnbaum, Daniel .

INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (01) :236-240

[6] The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin [J].

Bhattacharyya, A ;

Ear, US ;

Koller, BH ;

Weichselbaum, RR ;

Bishop, DK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23899-23903

[7] Does triple-negative phenotype accurately identify basal-like turnour?: An immunohistochemical analysis based on 143 'triple-negative' breast cancers [J].

Bidard, F.-C. ;

Conforti, R. ;

Boulet, T. ;

Michiels, S. ;

Delaloge, S. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2007, 18 (07) :1285-1286

[8] Early onset of breast cancer in a group of British black women [J].

Bowen, R. L. ;

Duffy, S. W. ;

Ryan, D. A. ;

Hart, I. R. ;

Jones, J. L. .

BRITISH JOURNAL OF CANCER, 2008, 98 (02) :277-281

[9] Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J].

Burstein, Harold J. ;

Elias, Anthony D. ;

Rugo, Hope S. ;

Cobleigh, Melody A. ;

Wolff, Antonio C. ;

Eisenberg, Peter D. ;

Lehman, Mary ;

Adams, Bonne J. ;

Bello, Carlo L. ;

DePrimo, Samuel E. ;

Baum, Charles M. ;

Miller, Kathy D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1810-1816

[10] Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models [J].

Caldas-Lopes, Eloisi ;

Cerchietti, Leandro ;

Ahn, James H. ;

Clement, Cristina C. ;

Robles, Ana I. ;

Rodina, Anna ;

Moulick, Kamalika ;

Taldone, Tony ;

Gozman, Alexander ;

Guo, Yunke ;

Wu, Nian ;

de Stanchina, Elisa ;

White, Julie ;

Gross, Steven S. ;

Ma, Yuliang ;

Varticovski, Lyuba ;

Melnick, Ari ;

Chiosis, Gabriela .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (20) :8368-8373

← 1 2 3 4 5 6 7 8 9 →